

Coverage, Billing, and Financial Assistance

For Foundation Medicine Patients

Our experience shows that

87%

of patients have \$0 financial responsibility

for Foundation Medicine Testing¹

As part of our FOUNDATIONACCESS™ program,

for each comprehensive genomic profiling test ordered, we complete a benefits investigation and **reach out to all patients whom we expect may have out-of-pocket costs.**

Insurance Coverage Information

- All Foundation Medicine tests are covered by Original Medicare² and Medicare Advantage³ for qualifying patients.^{4,5}
- Qualifying patients with Original Medicare² have no out-of-pocket costs for Foundation Medicine comprehensive genomic profiling tests.
- Health plans such as Cigna, UnitedHealthcare, Elevance Health (formerly Anthem), and many BlueCross BlueShield plans offer coverage for Foundation Medicine testing services. We will work directly with your insurance company to try to obtain coverage.⁶
- 80 health plans cover one or more Foundation Medicine CGP tests.⁷

Billing Information

- Foundation Medicine will make every attempt to support insurance coverage and payment for testing. If your insurance company denies coverage for a Foundation Medicine test, with your consent, we will work to obtain coverage and pursue appeals.
- Foundation Medicine only bills patients after following the entire claims process. Your out-of-pocket cost will depend on your insurance plan and may include deductibles, co-insurances, copays, or non-covered charges.

FOUNDATIONACCESS™

Foundation Medicine is committed to providing patients with resources and support throughout the testing process with the help of the FoundationAccess™ program. After your doctor orders a test and our lab receives your sample, we'll reach out to you by phone, or mail, with important information about what you can expect as your test moves forward.

- Foundation Medicine offers a needs-based financial assistance program for qualifying patients. Patients may apply for financial assistance at any point in the testing process at www.foundationmedicine.com/aid. Payment plans may also be available.

* Foundation Medicine's FoundationAccess™ program is only available to patients whose tests were ordered within the United States and U.S. territories.

Questions

You may receive an Explanation of Benefits (EOB) from your health insurance plan stating what medical services you received, including testing from Foundation Medicine. The EOB is not a bill. If you have questions about your EOB or about any other issue related to costs, please contact our Client Services Team. This team's priority is helping you.

Call: 888-988-3639

Email: client.services@foundationmedicine.com

Fax: 617-418-2290



References

1. Data on File, Foundation Medicine, Inc., 2022. Based on US settled claims from 1/1/21 to 3/31/22 for all CGP and IHC tests offered by Foundation Medicine and reported during that time before considering any financial assistance. 64% of commercially insured and 97% of Medicare and Medicare Advantage patients had a \$0 financial responsibility for Foundation Medicine testing. Some patients may have higher financial responsibility.
2. Medicare administered by federal government.
3. Medicare administered by private insurers.
4. For FoundationOne®CDx and FoundationOne®Liquid CDx, see "Decision for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced cancer - CAG-00450R." (See Appendix B) available in the Medicare Coverage Database, <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>.
5. For FoundationOne®Heme, see the "Local Coverage Determination (LCD): MoIDX: NEXT-GENERATION Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047) available in the Medicare Coverage Database, <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>
6. Many commercial payers have developed medical policy coverage for Foundation Medicine's FoundationOne CDx and FoundationOne Liquid CDx.
7. Data on File, Foundation Medicine, Inc., data current as of March 2023. Based on number of medical policies covering one or more Foundation Medicine CGP tests as medically necessary for qualifying patients who meet medical criteria. Even with medical policy that provides coverage, some plans may be out-of-network. Out-of-pocket patient responsibility will vary depending on plan details, network status, and whether providers are in or out-of-network.

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based *in vitro* diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients being considered for eligibility for therapy based on detection of *NTRK1/2/3* and *ROS1* fusions should only be tested if tissue is unavailable. Patients who are tested with FoundationOne Liquid CDx and are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible.

For the complete label, including companion diagnostic indications and important risk information, please visit www.FICDXLabel.com and www.FILCDXLabel.com.

FoundationOne®Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test, please see the Technical Specifications at www.foundationmedicine.com/heme.